Abstract
Peptide based vaccine design for cancer immunotherapy is currently being used in clinical trials for malignant melanoma with much success. Administration of synthetic peptides derived from proteins overexpressed in tumour cells (tumour-associated antigens) can elicit tumour-specific CD8+ T cell responses in vitro and in vivo. Currently, a number of tumour antigens from overexpressed cancer proteins such as mucin 1 (MUC1), survivin, carcinoembryonic antigen (CEA), telomerase reverse transcriptase (TERT) and HER- 2 / neu are examples of cancers whereby peptide based vaccinations are being tested for potential immunotherapy. In this review, we discuss some examples of the work being investigated with these cancer proteins, limitations to this therapy and suggestions of future directions to improve the efficacy of this treatment.
Keywords: peptide, cancer immunotherapy, tumour associated antigens, cytotoxic t cells, muc1
Letters in Drug Design & Discovery
Title: Peptide Based Vaccine Design for Cancer Immunotherapy
Volume: 1 Issue: 3
Author(s): D. S. Pouniotis, J. Halton and V. Apostolopoulos
Affiliation:
Keywords: peptide, cancer immunotherapy, tumour associated antigens, cytotoxic t cells, muc1
Abstract: Peptide based vaccine design for cancer immunotherapy is currently being used in clinical trials for malignant melanoma with much success. Administration of synthetic peptides derived from proteins overexpressed in tumour cells (tumour-associated antigens) can elicit tumour-specific CD8+ T cell responses in vitro and in vivo. Currently, a number of tumour antigens from overexpressed cancer proteins such as mucin 1 (MUC1), survivin, carcinoembryonic antigen (CEA), telomerase reverse transcriptase (TERT) and HER- 2 / neu are examples of cancers whereby peptide based vaccinations are being tested for potential immunotherapy. In this review, we discuss some examples of the work being investigated with these cancer proteins, limitations to this therapy and suggestions of future directions to improve the efficacy of this treatment.
Export Options
About this article
Cite this article as:
Pouniotis S. D., Halton J. and Apostolopoulos V., Peptide Based Vaccine Design for Cancer Immunotherapy, Letters in Drug Design & Discovery 2004; 1 (3) . https://dx.doi.org/10.2174/1570180043398894
DOI https://dx.doi.org/10.2174/1570180043398894 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Iron Chelators as Anti-Neoplastic Agents: Current Developments and Promise of the PIH Class of Chelators
Current Medicinal Chemistry Immunotherapy and Radiation Therapy in Renal Cell Carcinoma
Current Drug Targets Fluorescence Imaging in Cancerology
Current Molecular Imaging (Discontinued) Pro-Oncogenic Cell Signaling Machinery as a Target for Oncolytic Viruses
Current Pharmaceutical Biotechnology Merlin, a “Magic” Linker Between the Extracellular Cues and Intracellular Signaling Pathways that Regulate Cell Motility, Proliferation, and Survival
Current Protein & Peptide Science Role of the Sex Hormone Estrogen in the Prevention of Lipid Disorder
Current Medicinal Chemistry The Effects of Statin Therapy on the Human Airway
Drug Metabolism Letters Recent Advances in Small Molecule Inhibitors of VEGFR and EGFR Signaling Pathways
Current Topics in Medicinal Chemistry Overcoming the Hurdles of Tumor Immunity by Targeting Regulatory Pathways in Innate and Adaptive Immune Cells
Current Pharmaceutical Design Multicolor-FISH Approaches for the Characterization of Human Chromosomes in Clinical Genetics and Tumor Cytogenetics
Current Genomics Lung Cancer Chemotherapy, New Treatment and Related Patents
Recent Patents on Anti-Cancer Drug Discovery Quantitative Enzymology
Current Enzyme Inhibition Recent Developments in the Synthesis of Antitumor-active Glycyrrhetinic Acid Derivatives
Mini-Reviews in Organic Chemistry Synthetic and Natural Polycations for Gene Therapy: State of the Art and New Perspectives
Current Gene Therapy Antitumor Effect of Cycle Inhibiting Factor Expression in Colon Cancer <i>via Salmonella</i> VNP20009
Anti-Cancer Agents in Medicinal Chemistry Drug Delivery Nanoparticles in Treating Chemoresistant Tumor Cells
Current Medicinal Chemistry Niosomal Gel for Site-Specific Sustained Delivery of Anti-Arthritic Drug: In Vitro-In Vivo Evaluation
Current Drug Delivery High Frequency of the Opioid Receptor µ-1 (OPRM1) A118G Polymorphism, an Opioid Drug Therapy Related Gene, in the Indonesian Population
Current Pharmacogenomics and Personalized Medicine PET Tracers for Serotonin Receptors and Their Applications
Central Nervous System Agents in Medicinal Chemistry Smart Synthetic Polymer Nanocarriers for Controlled and Site-Specific Drug Delivery
Current Topics in Medicinal Chemistry